Tirzepatide is a once-weekly injectable medication that activates two hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism sets it apart from semaglutide, which targets only GLP-1 receptors. In the SURMOUNT-1 trial, tirzepatide produced an average weight loss of 20.9% at the highest dose over 72 weeks.

The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound. The same molecule is marketed as Mounjaro for type 2 diabetes management, approved in May 2022.

How the Dual Mechanism Works

GLP-1 receptors and GIP receptors both belong to a class of receptors stimulated by hormones released from the gut after eating. GLP-1 is well characterized: it suppresses appetite, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. GIP was historically considered to have limited therapeutic value, but combining GIP agonism with GLP-1 agonism appears to produce greater appetite suppression than either alone.

In the brain, both GLP-1 and GIP receptors are expressed in areas involved in appetite regulation and reward signaling. The combined activation of these receptors in the hypothalamus and brainstem produces stronger appetite suppression than GLP-1 activation alone, according to preclinical data. The clinical weight loss numbers support this: tirzepatide consistently produces higher average weight loss than semaglutide in separate trials, though the two drugs have never been directly compared head-to-head.

In fat tissue, GIP receptors are expressed in adipocytes. Tirzepatide activates these receptors, which may enhance insulin sensitivity in fat cells and affect fat storage directly. The exact contribution of GIP receptor agonism to weight loss, versus the enhanced GLP-1 component, is still being quantified in ongoing research.

In the pancreas, tirzepatide stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner, meaning it does not cause hypoglycemia at normal blood sugar levels. This mechanism is why both tirzepatide and semaglutide carry low hypoglycemia risk compared to older diabetes medications.

SURMOUNT-1 Trial Results

The SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI 30 or higher) or overweight with at least one weight-related condition, without diabetes. Participants received 5 mg, 10 mg, or 15 mg weekly or placebo, alongside lifestyle counseling, for 72 weeks. Published in the New England Journal of Medicine in 2022:

  • 5 mg dose: average weight loss of 15.0%
  • 10 mg dose: average weight loss of 19.5%
  • 15 mg dose: average weight loss of 20.9%
  • Placebo: average weight loss of 3.1%

At the 15 mg dose, 91% of participants lost at least 5% of body weight. 57% lost at least 20%. These are the largest weight loss numbers ever reported in a non-surgical, non-combination pharmacotherapy trial.

Side effects were primarily gastrointestinal: nausea, diarrhea, vomiting, and constipation. These occurred most frequently during dose escalation and declined after reaching maintenance dose. The rate of serious adverse events was similar between tirzepatide and placebo groups.

Dosing Schedule

Like semaglutide, tirzepatide uses a gradual dose escalation to reduce gastrointestinal side effects:

  • Weeks 1-4: 2.5 mg weekly
  • Weeks 5-8: 5 mg weekly
  • Weeks 9-12: 7.5 mg weekly
  • Weeks 13-16: 10 mg weekly
  • Weeks 17-20: 12.5 mg weekly
  • Week 21 onward: 15 mg weekly (maximum dose)

Not everyone reaches 15 mg. Clinicians often adjust the escalation schedule based on tolerability, and some patients achieve satisfactory results at 10 mg or lower.

Who Qualifies for Tirzepatide

The FDA approval for Zepbound covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.

Contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should not be used during pregnancy.

What Tirzepatide Does Not Do

Tirzepatide does not increase metabolic rate. The weight loss comes almost entirely from reduced caloric intake driven by appetite suppression. It is not a stimulant, and it does not burn fat directly. Exercise and adequate protein intake remain important during treatment to preserve lean muscle mass, which is lost along with fat during any significant weight loss.

Weight regain after stopping tirzepatide follows the same pattern documented for semaglutide: most of the weight returns within 12 months of discontinuation. The SURMOUNT-4 trial confirmed this, showing that participants who switched to placebo after achieving weight loss on tirzepatide regained most of their lost weight within a year.

For a direct comparison of tirzepatide and semaglutide trial data, see Tirzepatide vs. Semaglutide: What the Clinical Trials Actually Show. For the mechanism of the GLP-1 side of tirzepatide’s action, see What Is Semaglutide and How Does It Work for Weight Loss?